Wedbush analyst David Nierengarten lowered the firm’s price target on AnaptysBio (ANAB) to $50 from $70 and keeps an Outperform rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB: